Tulisokibart
MK-7240 / PRA023Merck's TL1A acquired from Prometheus April 2023 for $10.8B. Three active P3s in IBD plus broad indication expansion (HS, axSpA, RA, PsA).
Target: TNFSF15 monoclonal antibody (anti-TL1A) Merck Sharp & Dohme LLC Inflammation
When will we know if it works?
Fresh est.A positive readout makes TNFSF15 a validated target for the first time. Hover the badge above for what the confidence level means.
3
Phase 3 trials
3 active · 0 completed
12
Total trials
P2: 7 · P1: 2
1,380
Max trial size
across 11 indications
2
Sponsors at target
incl. 4 other assets
What does it do?
TNFSF15 — TL1A (TNF Superfamily Member 15)
Modality: monoclonal antibody (anti-TL1A)
Program: ATLAS-UC, ATLAS-CD
The 3 Phase 3 trials
| NCT ID | Indication | N | Status | Started | Primary completion | Readout |
|---|---|---|---|---|---|---|
| NCT06052059 | Ulcerative Colitis | 1,020 | ACTIVE_NOT_RECRUITING | 2023-10-25 | 2026-08-01 | Fresh est. |
| NCT06430801 | Crohn's Disease | 1,200 | RECRUITING | 2024-06-05 | 2028-10-30 | Fresh est. |
| NCT06651281 | Crohn Disease; Colitis, Ulcerative | 1,380 | RECRUITING | 2024-11-25 | 2037-12-17 | Stale est. |
What deals have been done?
| Year | Type | Counterparty | Value |
|---|---|---|---|
| 2023 | acquisition | Prometheus Biosciences | $10.8B |
What's the case for and against?
✓ What's working in its favor
- Phase 2 ARTEMIS-UC: 26% clinical remission rate at week 12 vs placebo 1.3%
- Companion diagnostic for predicted-responder enrichment (anti-DR3 biomarker)
- Indication expansion strategy with 4 separate P2 trials in 2025-2026
Who else is racing? — 4 other assets at TNFSF15
| Asset | Sponsor | Status |
|---|---|---|
| Afimkibart (RVT-3101) | Roche (via Telavant $7.1B) | P3 active |
| Duvakitug (TEV-48574) | Sanofi/Teva | Positive P2 readout 2024 |
| BB-TL1A-VIAL-HLE | BeiGene | P1 |
| BCD-261 | Biocad | P2 (Russia) |
Source: TheraRadar atomic trial table (built 2026-04-28 from ClinicalTrials.gov v2 API). Trial-target mapping validated via Gemini 2.0 + Gemini 3.1 Lite + Claude Haiku 4.5 multi-LLM consensus, with Claude Sonnet 4.6 arbitration. BD context curated by hand from public disclosures.